Figure 6

Evaluation of HER2 expression and of Ag-specific immune stimulatory activity in CT26/HER2-A2 cells by treatment with cytotoxic drugs. (A) CT26/HER2-A2 cells were incubated for 1 day with 1 μg/ml of drugs (5-FU, gemcitabine, cisplatin, holoxan, bleomycin, padexol). The tumor cells were lysed in RIPA buffer, and 30 μg samples of the cell lysates were separated by SDS-PAGE and analyzed by Western blot assay. (B) Mice were immunized by IM-EP with HER2 DNA vaccines at 0 and 1 weeks. At 2 weeks, the mice were sacrificed to obtain splenocytes. The splenocytes were incubated for 2 days with CT26/HER2-A2 cells that had been treated for 1 day with 1 µg of each drug per ml and then exposed to UV light for 3 h prior to immune cell treatment. The cell supernatants were collected for IFN-γ assay. *p < 0.05 compared to CT26. **p < 0.05 compared to control mice.